Alpha Score of 52 reflects moderate overall profile with strong momentum, strong value, poor quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 8.97M | $111.69M | NEW |
| D.E. Shaw David Shaw | 6.04M | $75.23M | NEW |
| Greenlight Capital David Einhorn | 3.36M | $36.34M | NEW |
| Marshall Wace | 403K | $5.02M | NEW |
Viatris Inc. is a global healthcare company that develops, manufactures, and markets a broad portfolio of branded and generic pharmaceutical products. It specializes in generics, including commoditized and complex varieties as well as biosimilars, alongside legacy branded medicines such as Lipitor, Norvasc, Lyrica, and Viagra. The company addresses multiple therapeutic areas, including cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare, with particular focus on dermatology, ophthalmology, and gastroenterology. Viatris Inc. serves patients in over 165 countries through its extensive product offerings in the specialty and generic drug sectors. Founded in 2019 and headquartered in Canonsburg, Pennsylvania, it operates as one of the largest generic drug manufacturers worldwide, providing essential medicines and treatments to diverse healthcare markets.
Earnings calendar coming soon. Subscribe to get notified when VTRS reports next.
Get earnings alerts →